New hope for patients with aggressive lymphoma that Won't respond
NCT ID NCT03011814
Summary
This study is testing two drugs, durvalumab and lenalidomide, to see if they can help control advanced T-cell lymphomas that have come back or stopped responding to other treatments. It aims to find the safest dose and see how well the drugs work, either alone or together, for patients who have already tried at least two other therapies. The main goals are to see if the treatment shrinks the cancer and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.